Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Serum neurofilament light… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease

Artikel i vetenskaplig tidskrift
Författare R. Sanchez-Valle
A. Heslegrave
M. S. Foiani
B. Bosch
A. Antonell
M. Balasa
A. Llado
Henrik Zetterberg
N. C. Fox
Publicerad i Alzheimers Research & Therapy
Volym 10
ISSN 1758-9193
Publiceringsår 2018
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Språk en
Länkar dx.doi.org/10.1186/s13195-018-0439-...
Ämnesord Alzheimer's disease, Biomarkers, Familial Alzheimer's disease, Presenilin 1, Neurofilament light, amyotrophic-lateral-sclerosis, frontotemporal dementia, biomarker, chain, association, protein, trials, Neurosciences & Neurology
Ämneskategorier Neurologi

Sammanfattning

BackgroundBiomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups.MethodsSerum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests.ResultsForty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho=0.75, p<0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho=0.70, p<0.001) and cognitive (rho=-0.77, p<0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho=0.72, 0.71, and 0.71, respectively, all p<0.001). Serum NfL concentration was higher in SMC than in AMC and CTR.ConclusionsSerum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?